Background Clinical studies have shown that the efficacy of TCZ monotherapy (TCZ mono) is superior to that of TNFi monotherapy and comparable to that of TCZ in combination with MTX.
Objectives To compare the effectiveness of TCZ mono vs TNFi plus varying doses of MTX in patients with rheumatoid arthritis (RA) and prior exposure to TNFi in routine clinical practice.
Methods Eligible participants were TCZ-naïve patients from the Corrona RA registry who had prior exposure to ≥1 TNFi, initiated TCZ mono or a TNFi + MTX between 2010 and 2016 and had a 6-month follow-up visit. The primary outcome was mean change from baseline in Clinical Disease Activity Index (CDAI) at 6 months. Secondary outcomes included achievement of low disease activity (LDA; CDAI ≤10) at 6 months. Patients initiating a TNFi + MTX were grouped by MTX dose (≤10 mg; >10 to ≤15 mg; >15 to ≤20 mg; >20 mg); outcomes in each group were compared with those initiating TCZ mono using trimmed populations, excluding patients outside the propensity score (PS) distribution overlap (not on common support). The PS included age, sex, race, body mass index, smoking status, work status, disease duration, concomitant prednisone use/dose, prior biologic use, American College of Rheumatology functional class and baseline modified Health Assessment Questionnaire, CDAI and patient pain scores. As a sensitivity analysis, stratified-matched populations were created (stratified by 1 vs ≥2 prior biologics, then matched on PS). Linear and logistic regression models were estimated in the trimmed populations, adjusting for the same covariates as in the PS.
Results Baseline demographics were generally comparable between the TNFi + MTX groups and their matched TCZ mono groups. Overall, the mean age was 54 to 59 years, and the mean disease duration was 10.5 to 15 years. A higher proportion of patients initiating TCZ mono had received ≥3 prior biologics compared with those initiating TNFi + MTX. Patients initiating TCZ mono had significantly longer mean disease duration than those initiating TNFi + MTX >15 to ≤20 mg (13.0 vs 10.5 years) or TNFi + MTX >20 mg (12.3 vs 9.3 years) and a higher mean baseline CDAI than those initiating TNFi + MTX ≤10 mg (28.1 vs 25.4). Patients in all groups had improvement in CDAI scores at 6 months. In adjusted models, improvement in CDAI and the likelihood of achieving LDA were similar between the TCZ mono group and all TNFi + MTX groups (Table). Similar results were observed in the PS-matched cohorts.
Conclusions TCZ mono was as effective as TNFi + MTX, regardless of MTX dose, for improving disease activity in patients with prior TNFi exposure. These data suggest that TCZ mono is an effective treatment option for patients with RA who cannot tolerate or prefer not to use MTX.
Acknowledgements This study is sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the past 2 years by AbbVie, Amgen, BMS, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche and UCB.
Disclosure of Interest L. Harrold Shareholder of: Corrona, LLC, Grant/research support from: Pfizer, Consultant for: Roche, Employee of: University of Massachusetts Medical School; Corrona, LLC, G. Reed Shareholder of: Corrona, LLC, Employee of: Corrona, LLC, J. Best Employee of: Genentech, Inc, S. Zlotnick Employee of: Genentech, Inc, G. Persuitte Employee of: Corrona, LLC, J. Kremer Shareholder of: Corrona, LLC, Consultant for: AbbVie; Amgen; Bristol-Meyers Squibb; Genentec, Inc; GlaxoSmithKline; Lilly; Pfizer; Regeron; Sanofi, Employee of: Corrona, LLC